It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the...
Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.
The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $120 million with plans to stake a new generation of biotechs.
For the past 35 years, Atlas Venture has operated as a diversified investor, splitting its efforts between technology and life sciences. Starting next year, the two sides will part.
European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.
A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.
Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.
Eight months after partnering with Novartis, Emeryville, CA-based Eureka Therapeutics has landed a $21 million round led by a Chinese private equity firm. Beijing-based Yuan Capital led the round, with Majuven and all the current major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, joining in.
BBK Worldwide has raised $3 million to finance an expansion of its suite of eClinical software.
The University of California has been a rich source of innovative new medicines. It's outlicensed the IP behind such standout biotechs as Aragon and Seragon--twin biotech sisters bought out by pharma giants--as well as Kite Pharma, a recent IPO success focused on CAR-T. And now it wants a bigger piece of the action.